Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas, explains the process of Mohs surgery for removing skin cancers and preserving healthy surrounding tissue.
Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas, explains the process of Mohs surgery for removing skin cancers and preserving healthy surrounding tissue.
Transcript
What is Mohs surgery and how is it utilized for patients with skin cancers?
The whole point of Mohs surgery is to remove a skin cancer, with the smallest amount of normal skin and the highest chance of cure and the lowest chance of recurrence. Mohs surgery has a set of appropriate-use criteria, and most dermatologists will be aware of those criteria. In a nutshell, we're talking tumors that are in sensitive areas of the body: the central part of the face, the ears, the temples, the scalp, the nose, the lips, fingers, genital areas, things like that. We're looking where we want to spare tissue, and we want to remove the cancer with the smallest amount of normal skin around it.
The other big important piece of Mohs surgery is the way that pathology slides are processed. The key is that they're processed so that way 100% of the surgical margin is examined in 1 plane. As you slice through the specimen, you can see all the way around the edges and you can see the center at the same time—that’s what you see when you do the first layer of Mohs. This is a micrographic, highly controlled type of surgery with a high cure rate.
The other important point is that the surgeon is also the pathologist, so the same person is removing the tissue and seeing what's going on clinically with a patient and the tumor bed. They're also reading the slides and comparing those, too, and that comparison that's done by that 1 person improves the accuracy tremendously over traditional surgery.
Mohs surgery is a highly accurate, microscopically controlled surgery that can help our patients get clear of tumors with the lowest chance of recurrence.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
ctDNA Monitoring Can Predict Early Melanoma Recurrence Following Resection
May 2nd 2025Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of early recurrence.
Read More
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More